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ABSTRACT 
An abstract of the thesis of Shin Chen for the Master of 
Science in Biology presented July 6, 1994. 
Title: The DNA Sequence Required for the Maximal Trans-
activation of the VP5 Gene of Herpes Simplex Virus 
Type 1. 
A regulatory element involved in the transcriptional 
activation of the major capsid protein (VP5) of herpes 
simplex virus type 1 was identified and characterized in 
this research project. Gel mobility shift assay with 
nuclear extracts from both uninfected and HSV-1 infected 
HeLa cells identified two major protein-DNA complexes 
involving the VP5 promoter. No viral specific complex 
found. DNase I and orthophenanthroline-cu+ footprint 
analyses in the same laboratory revealed that the two 
complexes involve a single binding site, GGCCATCTTGAA, 
located between -64 and -75 bp relative to the VP5 cap site. 
To determine the function of this leaky-late binding site 
(LBS) in VP5 gene activation, mutated VP5 promoters with 
deletion and insertion around LBS were constructed and 
linked to a reporter gene, bacterial chloramphenicol 
2 
acetyltransferase gene. The effect of mutations were tested 
in transient expression assay. Deletion of LBS resulted in 
seven to eight-fold reduction in the level of 
transactivation of the chloramphenicol acetyltransferase 
gene by superinfection with HSV-1 or by cotransfection of 
HSV immediate-early genes. These results indicated LBS is 
involved in the maximal transactivation of the VPS gene. A 
search of published gene sequences found the homologs of LBS 
exist in a number of HSV-1 py promoters, and other viral 
promoters, as well as cellar promoters. Some of these 
homologs have found involved in the transcription 
regulation. 
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CHAPTER I 
INTRODUCTION 
The herpesvirus family, Herpesviridae, contains nearly 
100 viruses that infect different eukaryotic species, from 
fungi to humansl. It was named for those members who are 
responsible for some common human diseases, the herpes 
simplex viruses. Herpesviruses also are found in other 
living organisms, e.g. B virus of monkeys (occasionally 
infect humans), pseudorabies virus of pigs, virus III of 
rabbits, and oncogenic viruses that produce lympho-
proliferative malignancies in chickens and monkeys. Based on 
host range, replication features and latency, Herpesviridae 
is divided into three subfamilies: alphaherpesvirinae 
(includes the herpes simplex type 1 and 2 viruses and the 
varicella zoster virus), betaherpesvirinae (cytomegalovirus, 
human herpesviruse 6 and 7), gammaherpesvirinae, (Epstein-
Barr virus). Within the subfamilies, viruses are further 
divided into genera based on DNA sequence homology, 
similarities in genome sequence arrangement, and relatedness 
of virion proteins as demonstrated by immunologic methods. 
Alphaherpesvirinae have a variable host range and short 
reproductive cycle. They spread rapidly in culture, 
efficiently destroy infected cells, and cause latent 
infections primary in sensory ganglia. Betaherpesvirinae 
have restricted host range. Their reproductive cycle is 
long, and their infection progresses slowly in culture. The 
virus can be latent in secretory glands, lymphoreticular 
cells, kidneys, and other tissues. The gammaherpesvirinae 
are specific for either T or B lymphocytes, and they 
frequently exist as latent viruses in lymphoid tissue. 
GENERAL BACKGROUND OF HSV 
2 
Seven herpesviruses have been isolated from humans, 
herpes simplex virus type 1 (HSV-1) and herpes simplex virus 
type 2 (HSV-2), varicella zoster virus (VZV), human cyto-
megalovirus (HCMV), Epstein-barr virus (EBR), human 
herpesvirus 6 (HHV 6) and human herpesvirus 7 (HHV 7). 
Herpesviruses are very important for human beings. In 
America, over 87% of the population have been infected by one 
or more herpesviruses. 
Herpes simplex viruses (HSV) were the first human 
herpesviruses to be discovered and are one of the most 
intensively investigated viruses. Herpes simplex viruses 
causes a wide variety of clinical infections, ranging from 
inapparent infection and focal cytopathogenicity to fatal 
encephalitis. An interesting feature of these viruses is 
their ability to establish a latent infection in neurons of 
the sensory ganglia, here they persist for the life time of 
the host, and they may periodically be reactivated to cause 
skin lesions and other disease symptoms. 
As with many other known herpesviruses, HSV shares four 
significant biological properties: 
1) HSV characteristically encodes a diverse array of 
enzymes involved in nucleic acid metabolism and DNA 
synthesis. 
2) Both the synthesis of viral DNAs and the assembly of 
capsids occur in the nucleus. 
3) Irreversible destruction of the infected cell is the 
consequence of infectious progeny virus production. 
4) The viruses are able to become latent in neurons. 
In some cases, the latent viral genomes take 
the form of closed circular molecules and only one 
viral gene region is expressed2. 
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Herpes simplex viruses type 1 and type 2 can be 
distinguished by neutralization titration and by their 
distinct clinical patterns. Both types show cross reactivity 
antigenically and share approximately 50% homology in their 
genomes. They differ in restriction endonuclease cleavage 
sites and in the apparent sizes of viral proteins. Herpes 
simplex viruses exhibit focal cytopathogenicity. The type 1 
virus is primarily associated with oral and ocular lesions 
and is transmitted by oral and respiratory secretions, 
whereas type 2 is isolated primarily from genital and anal 
lesions and is generally passed through sexual contact. 
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Fever blisters or cold sores are the common diseases that 
result from HSV-1 infection. The more severe infection may 
cause 1) disseminated disease to visceral organs, 2) severe 
deep ocular involvement which can lead to blindness, or 3) 
herpes encephalitis. HSV-2 is the causative agent for herpes 
genitalis and generalized herpes of newborn. It is also 
frequently associated with cervical carcinoma. For example, 
HSV-2 has been isolated from 85% of the cervical carcinoma 
patients. HSV-1 usually establishes latent infection in 
neurons of the trigeminal ganglia, whereas HSV-2 generally 
become latent in sacral ganglia. 
Virion structure 
Herpes simplex type 1 is an enveloped virus of about 
150 nm on diameter (Fig. 1). As with all herpes virons, the 
HSV-1 virion consists of four elements: (1) an electron dense 
core, (2) an icosadeltahedral capsid surrounding the core, 
(3) an amorphous tegument surrounding the capsid, and (4) an 
outer envelope containing many viral glycoprotein spikes on 
its surface. The electron dense core is about 75 nm in 
diameter, and it contains the linear, double-stranded DNA 
genome of the virus. The structural features of the capsid, 
95 to 100 nm in diameter and comprised of 162 capsomeres, are 
characteristic of all the herpesviruses. The capsid is 
composed of a number of viral proteins, at least eight of 







FIG. 1. Diagram of a virion of Herpes simplex virus. 
VP23, VP24, and 12 Kd protein. The tegument, the granular 
zone surround the capsid, contains the virion host shut-off 
(vhs) protein, the a-trans-inducing factor (variously 
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described as a-TIF, ICP25, or VP16, a protein required for 
activating immediate-early gene transcription), immediate-
early proteins ICP4 and ICPO, and a very large protein (VPl) 
associated with a complex that binds to the terminal "a" 
sequence of the viral genome3,4. The envelope is derived 
from the inner membrane of the host cell nucleus modified by 
the insertion of viral glycoproteins. These glycoproteins 
are gB, gC, gD, gE, gG, gH, gI, gJ, gK, gL and gM. Three of 
them (gB, gD, and gH) are clearly indispensable for viral 
replication, the rest of them are dispensable in cell culture 
for both entering into cell and releasing from cells, 6 
HSV-1 Genome 
The genome of HSV-1 consists of one linear double-
stranded DNA of 152 kilobasepairs with a molecular weight of 
100 x 106 daltons. It is composed of two regions, a long 
region (L) and short region (S) which comprise 82% and 18% of 
the viral DNA, respectively (Figure 2). Each of these 
regions consists of unique sequences bracketed by inverted 
repeat sequences. The repeats of long region are designated 
ab and b'a', whereas the repeats of the short region are 
designated a'c' and ca. The number of a sequence repeats at 
the L-S junction and at the termini is variable. 
, a 
b'a c' c 
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FIG. 2. Diagrams of the physical structures of genomes of 
several viruses of the family Herpesviridae. The genomes 
are composed of unique long (UL) and unique short (Us) 
region. Terminal repeats (TR) bound the genome, and 
inverted repeats (IR) bound the. unique regions. 
(Dulbecco. 1988) 
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The HSV-1 a sequence is approximately 85% G+C and 200 
to 500 bp in length. It contains 20 bp direct repeats on 
each end and two unique segments separated by internal 
directly repeated regions. The structure of the terminally 
repeated a sequence is highly conserved but contains a 
variable number of internal repeat elements. The size of the 
a sequence also varies from strain to strain. The a 
sequence is involved not only on recombination, but also in 
processing and packaging the viral DNA. 
During the replication, recombination occurs through 
the inverted repeats of a sequence and gives rise to 
different isomeric forms of the genome, and recombination is 
closely associated with viral DNA replication7. The ability 
to exist as four linear isomers which differ in the relative 
orientations of the long region and short region is a 
property of herpes simplex virus shared, in part, with 
several other herpesviruses (Figure 3) . Viral DNA prepared 
from purified virion consists of four isomers present in 
equal molar amounts. These isomers have been designated as P 
(prototype), IL (inversion of the L region), Is (inversion of 
the S region), ILs (inversion of both Sand L regions). The 
a sequence and viral trans-acting factors are required for 
inversion. The physiologic function of the inversion of L 
and S regions is not clear. However, a HSV-1 mutant that is 
locked in one orientation is perfectly viable8. 
A. 
a b b' a' a' c' c a 
I I I I I I I 
L S 
4 ~4 ~ 
FIG. 3. Schematic representation of the arrangement of DNA 
sequences in the HSV genome. A. The domins of the L and S 
components are denoted by the arrows. B. The four isomers of 
the HSV DNA. 
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Viral Replication 
HSV-1 viruses have a rather wide host range of both in 
vitro and in vivo. Infection start with attachment which is 
mediated by the binding of viral glycoproteins to heparan 
sulfate moieties of cell surface, and enzymatically removal 
of heparan sulfate from cell greatly reduced the level of 
attachment and infection of those ce119. Spear and 
colleagues also showed that either glycoprotein gB or gC is 
required for attachment. Although gC is dispensable for 
replication of HSV in cell culture, it facilitates virion 
adsorption to cells and enhances infectivity by about a 
factor of 10 10. The attachment activates a penetration 
process mediated by viral surface proteins which cause the 
fusion of the viral envelope with the cell plasma membrane. 
Glycoproteins gB, gD and gH are indispensable for the fusion 
of the viral envelope and cell membrane 11, 12, 13. 
After penetration, the viral nucleocapsid is 
transported along the cytoskeleton from the site of entry to 
nuclear pores. There the viral DNA and is released into the 
nucleus. There are virion components protect and facilitate 
the entry of the DNA into cells, and also appear to be 
involved in the early shut off of host macromolecular 
synthesis. The linear, double-stranded viral DNA circularizes 
immediately upon release from capsid. Once in the nucleus, 
the viral DNA is transcribed by host RNA polymerase II with 
the participation of various viral and cellular factors. HSV 
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mRNAs are capped, methylated, and polyadenylated, and only 
small proportion of viral mRNAs are derived by splicing. The 
abundance and stability of the various HSV-1 mRNAs appear to 
vary. 
Viral DNA synthesis is carried out by viral proteins 
and host cell enzymes in nucleus. There are three origins of 
DNA replication: two in the terminal repeat sequences of 
short region, between the promoters of ICP4 and ICP22(ori 1) 
or ICP4 and ICP27(ori 2), and one(ori 3) in the middle of the 
unique long region between the genes encoding the DNA 
polymerase and the DNA binding protein (ICP8)14. By 
transfecting cells with a plasmid containing an origin of DNA 
synthesis and various fragments of the HSV genome, genetic 
studies have shown that seven genes are essential for HSV 
origin-dependent DNA replication: UL9 encodes an origin 
recognition protein15; ULS, UL8, and UL52 encode the three 
subunites of a helicase-primase complex16; UL29 encodes a 
single-strand DNA binding protein ICP817; UL30 encodes a DNA 
polymerase18; and UL42 encodes a double-strand DNA binding 
protein that is a subunit of DNA polymerasel9. 
The translation of viral mRNAs occurs in the cytoplasma 
on both bound and free polyribsomes. Most of the proteins 
seem to be processed extensively. Processing includes 
cleavage, phosphorylation, sulfation, glycosylation poly(ADP-
ribosyl)ation, and nucleotidylylation. Structural proteins 
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and most regulatory proteins are transported into the nucleus 
where new capsid assembly occurs. 
The concatemeric viral DNA synthesized by a rolling 
circle mechanism is cleaved at terminal repeats in the a 
sequence and packaged in preformed capsid. These particles 
are unstable and noninfectious until they acquire envelope. 
Unlike other enveloped virus, the envelopment occurs at the 
inner lamella of the nuclear membrane which has been modified 
by viral glycoproteins. The release of virus does not occur 
by budding from plasma membrane, rather through the cisternae 
of the endoplasmic reticulum which extend to the plasma 
membrane (see Figure 4) 
HSV-1 GENE EXPRESSION 
The cascade of HSV-1 gene expression 
The DNA sequence of the 152-kilobase genome of herpes 
simplex virus type-1 (HSV-1) has been determined. It encodes 
at least 72 unique proteins20,21. Fifty six of the open 
reading frames are in UL region, twelve are in Us and one 
each in the repeat regions. Although the function of many of 
these genes has been determined, there are still many whose 
function in either viral replication or viral pathogenicity 
is not known. The transcription of viral DNA takes place in 
the nucleus by host RNA polymerase II and all viral proteins 
are synthesized in the cytoplasm. During the productive 
infection, the synthesis of these proteins is temporally and 
~~ lm:::!ate A I j\ I -> J 11\ . ~ /)I ~y-. e .. .., ) ~- .. ......, 
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FIG. 4. Sequence of events in the multiplication of 
herpes simplex virus from entry of the virus into the 
cell by fusion of the virion envelope with the host 
membrane to assembly of virions and their exit from the 
cell through the endoplasmic reticulum. (Dulbecco 1988) 
quantitatively regulated, primarily at the transcriptional 
level by cis-acting signals within the viral genome and 
trans-acting factors encoded in both the host and viral 
genomes22,23. Based on this cascade fashion of gene 
expression, the viral genes were classified into three 
kinetic classes which were designated as immediate-early 
(alpha), early (beta), late (gamma)24, 25. 
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Alpha genes are those that are expressed in the absence 
of viral protein synthesis. The synthesis of a polypeptides 
reaches maximal rates at approximately 2 to 4 hours post-
infect ion and they accumulate until late in infection. HSV-1 
encodes four a proteins which have been shown to affect the 
expression of HSV-1 genes, namely, infected cell polypeptides 
ICPO (IEllO), ICP4 (IE175), ICP22 (IE68), and ICP27 (IE63). 
The function of the fifth a protein, ICP47 (IE12), has not 
been established, but does not appear to affect HSV-1 gene 
expression in tissue culture26. In addition to the five a 
genes, the latency-associated transcript 1 (LATl) and a 
transcript designated as Oris RNA are transcribed under a 
conditions(i.e. in the absent of protein synthesis). 
Beta genes are not expressed in the absence of a 
proteins and their expression is enhanced in the presence of 
inhibitors of viral DNA synthesis. The P transcripts can be 
detected 2 hours postinfection. Their synthesis reaches 
maximal rate following the initiation of DNA replication, 
about 5 to 6 hours post-infection and gradually decrease to 
15 
nearly undetectable levels late in infection. Subgroup ~1, 
that includes ICP6 (ribonucleotide reductase) and ICP8 (the 
major DNA-binding protein), are expressed earlier than 
subgroup ~2 which includes ICP36 (viral thymidine kinase) and 
HSV DNA polymerase. The P genes primarily encode products 
required for DNA synthesis, and the appearance of their 
products signal the onset of viral DNA synthesis (about 2 to 
3 hours post-infection) . 
The expression of late genes require the prior a and P 
gene expression. Late genes specify virion structural 
proteins and have been divided into two subgroups, py(or yl) 
and y(oril.), based on the sensitivity of their expression to 
DNA inhibitors. Low level of py genes (gB, gD and VPS) 
transcripts are detectable prior to viral DNA synthesis, 
whereas essentially no y gene (e.g. gC, USll and UL38) 
transcription is observed. Following the initiation of viral 
DNA replication, 2 to 3 hours post-infection, both py and y 
expression increase and reach peak level at 7 to 8 hour post-
infection and remain at high level late in infection. 
Regulation of HSV-1 gene expression 
The regulation of HSV-1 gene expression has become a 
major focus of research, and the mechanism by which the virus 
regulates its replication remains an exciting area of 
investigation. 
16 
The expressions of a genes are induced by a-TIF (Vmw65 
or VP16), which is a virion phosphoprotein synthesized late 
of infection and incorporated into tegument during virion 
assembly. When a-TIF is released into infected cell, it 
induces viral immediate-early gene expression via two 
cis-acting elements, the TAATGARAT and GCGGAA consensus 
sequences present in the IE promoters27( see figure 5). 
Alpha-TIF does not bind to DNA itself, but it forms a complex 
with cellular transcriptional factor Oct-1 (NFIII, OTF-1), 
and Oct-1 directly bind to the consensus sequences of IE 
promoters. Kristie and Sharp demostrated that at very high 
concentration, a-TIF could form complexes with DNA in the 
absence of Oct-128. This function is dispensable in tissues 
culture at high multiplicity, but is required for normal 
virus replication at low multiplicity of infection. 
Therefore, the IE gene expression is not totally dependent on 
the activity of a-TIF. 
All immediate-early proteins except ICP47 are nuclear 
phosphoproteins, and they regulate their own synthesis as 
well as the protein synthesis of other kinetic classes. 
Studies using viral ICP4 gene mutant have shown that ICP4 is 
involved in autoregulation of its own expression as well as 
that of other a genes, and it activates of p, py, and y 
expression29, 30. Transcription of p (ICP8), py (ICP5, gB), 
and y (gC) genes is dependent on rcp431, 32. ICP4 represses 
expression from its own promoter and the ICPO promoter by 


























FIG. 5. Diagram of the cascade regulation of HSV-1 transcription. 
L (y) 
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binding to a specific sequence, ATCGTC, near the 
transcriptional start site33, 34, 35. Mutations which 
eliminated DNA binding of ICP4 also eliminated or reduced 
both ICP4 transactivation and autoregulation indicating that 
DNA binding of ICP4 is required for these functions36. 
Studies have shown that HSV-1 infected cells that expressed 
defective ICP4 failed to: 1) activate the transcription of 
early and late genes, 2) induce viral DNA synthesis, and 3) 
down regulate immediately-early gene expression37. The HSV-1 
tk, a ~ gene is efficiently expressed only in the presence of 
IE gene products38. Faber and Wilcox's studies have 
attempted to define the tk promoter domains required for ICP4 
induced expression. None of the tk sequences that interact 
with ICP4 contains a consensus binding site for ICP4. This 
result suggest the ability of ICP4 to interact with more than 
one DNA sequence. 
ICP27 is an essential gene which has both activator and 
repressor functions. In the absent of functional ICP27, a 
genes are overexpressed, whereas the viral DNA replication 
reduced and late genes poorly expressed. In transient assay, 
ICP27 appears to have little or less effect alone on most 
HSV-1 promoters, but has two different effects on combination 
with ICPO and ICP4, depending on the target genes. A strong 
repression was observed in transfection of immediate-early 
(ICPO, ICP27), early (TK), and leaky-late(gB, gD) and late 
(gC) promoters with these three IE, whereas increased 
19 
transactivation were shown with a early promoter (alkaline 
exonuclease) and a leaky-late promoter (VP5)39, 40. Analysis 
of the mutant phenotypes demonstrated the genetic evidence 
for these two distinct transactivation functions of rcp2741, 
42 Cells infected with deletion mutants of ICP27 synthesize 
viral DNA, but late genes (y) are not expressed43. Sandri-
Goldin, et al. recent study showed the major effect of ICP27 
appears to be at post-transcriptional leve144. 
In contract to ICP4 and ICP27 which were absolutely 
essential for virus replication, ICPO deletion mutant grow as 
well as wild-type virus and produce same amount of viral 
proteins at high multiplicities of infection, but grow poorly 
and produce a less amount viral proteins at low multi-
plicities. Therefore, ICPO is important but not essential in 
viral production cycle. Transient expression assays have 
shown that ICPO is a strong trans-activator of all classes of 
viral HSV-1 genes as well as a number of cellular genes. The 
mechanism by which ICPO transactivates viral and eukaryotic 
promoters is unclear. Available evidence shows that ICPO 
activates many promoters although it does not appear to 
require any cis-acting element for this activity45. ICPO and 
ICP4 can stimulate expression of HSV-1 early and late 
promoters synergistically, since increased levels of 
induction have been observed when both are present than with 
either one alone46, 47 
There is no evidence indicating that ICP22 or ICP47 
affect viral gene expression in transient expression assay, 
although in certain cell types ICP22 is essential for 
efficient viral replication and late gene expression48. 
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The ~ genes are under the control of promoters that are 
active at low levels in uninfected cells or high levels in 
infected cells. The p promoters are activated by ICP4 and 
ICPO, or can be stimulated by exogenous enhancers (e.g. 
simian virus 40)49. Most of p gene products are proteins 
involved in viral DNA synthesis, and may have both positive 
and negative regulatory functions. Godowski and Knipe have 
suggested that in addition to its DNA binding function, ICP8 
may be important, also, in the maintenance of the highly 
ordered cascade of viral gene expression since defects in the 
ICP8 protein result in increased mRNA level of a (ICP4), p 
(ICP8), py (ICPS) and y (gC). ICP8 is required for shut-off 
of transcription of ICP4 and decrease in the transcription of 
p, py genes. 
The promoter structure of late genes is least 
understood and highly varied. Late genes do not appear to be 
efficient-ly expressed in uninfected cells. Temperature 
sensitive mutants studies have shown that ICPO, ICP4 and 
ICP27 are essential for efficient expression of late 
promoters. Except for an ICP4 binding site in the gD 
promoter50, extensive mutational analyses have not uncovered 
cis-acting sequences in leaky late promoters that are 
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specifically required for activation by IE proteins. The 
TATA element is the only consensus sequence identified in the 
upstream regulatory region of true late promoters51. 
Deletion studies have indicated that little upstream sequence 
from TATA element is required for efficient expression of 
true late genes, but sequences downstream from the TATA 
element are important even though no consensus sequence have 
been identified52. Homa et al. suggested that true late 
promoter activity requires a specific type of TATA element, 
since tk TATA box was unable to function when it was moved to 
the gC locus. The inhibition of viral DNA replication causes 
a moderate reduction in the accumulation of ~y mRNAs and a 
strong reduction of the accumulation of y mRNAs53. 
THE GENE OF MAJOR CAPSID PROTEIN 
The architecture of capsid is one of the characteristic 
features of the herpesvirus family. Capsid consists of 150 
hexavalent capsomers which form the edges and faces of the 
icosahedron and 12 pentavalent capsomers that are located at 
the capsid vertices. There are three distinct types of 
capsids that can be isolated from the nuclei of herpesvirus 
infected cells. Type A are the capsids that lack DNA and are 
never enveloped; type B contains DNA but are never enveloped; 
type C contains DNA and are obtained by de-enveloping intact 
virus. Empty capsids consist of five proteins, VPS, VP19C, 
VP23, VP24, and a small protein54; type B capsid contains two 
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additional proteins, VP21 and VP22a; instead of VP22a, type C 
capsid contains VP22. 
The major capsid protein (VP5) constitutes 
approximately 60% of the total capsid B mass and is 
considered to be the basic component of the hexavalent 
capsomers. In 1979, Anderson et al. reported that a 6 Kb 
mRNA was the most abundant viral transcript associated with 
polyribosome late in infection. In 1981, Costa et al. mapped 
this 6 Kb mRNA between 0.23 and 0.27 map units of the viral 
genome (Figure 6). In 1984, this 6 kb mRNA was able to be 
translated in vitro into a protein with molecular weight of 
155,000. By using a polyclonal antibody made against 
purified HSV-1 VP5, Costa et al. confirmed the product of 6 
Kb mRNA was the major capsid protein VP5. 
The gene encoding VP5 belongs to leaky-late or ~y class. 
Like true late genes, the promoter structure of leaky-late 
genes and the requirements of leaky-late gene expression 
remain mostly mystery. Despite the requirement of DNA 
replication for maximal expression, the VP5 promoter has all 
the features of a typical eucaryotic transcriptional 
promoter, and it has served as a good model for the ~y class 
genes. VPS promoter is inactive in uninfected cell. In a 
transient assay using a reporter plasmid, the VPS promoter 
was not active in uninfected cells55. In addition, a HeLa 
cell nuclear transcription extract did not initiate 
transcription of VPS under the conditions in which ~ gene 
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FIG. 6. (a) Location of Kpn I i fragment in the HSV-1 
genome (Preston et al., 1978). (b) Location of VPS mRNA 
in Kpn I i fragment. The size of the mRNA are indicated 
above the transcripts. The kinetic class and apparent 
molecular weights(x103) of in vitro translation products 
are indicated below the transcripts. (c) Location of 
protein coding regions in Kpn I i. Each open reading 
frame is shown as an open arrow. The approximate 
molecular weights of encoded proteins are indicated. 
transcription was initiated. However, a VPS promoter was 
readily transactivated in transient expression assay either 
by HSV super-infection or a gene ICPO, ICP4, and ICP27 
cotransfection56, 57. The level of activation of VPS 
promoter was directly proportional to the level of ICP4 
expressed in the cell line58. In addition to IE proteins, 
studies using inhibitors of viral DNA synthesis have shown 
that the viral DNA replication was also required for VPS 
maximum expression. But the mechanism of this coupling is 
unclear. 
24 
Detailed studies of the expression of a reporter gene 
under the control of various length VPS promoters in 
transient expression assays showed that 75 bp upstream 
sequence of VP5 promoter was active at low levels in 
uninfected cells, and it was sufficient to allow higher 
expression with HSV super-infection even though the 
expression level was lower than the maximum level driven by 
125 bp of upstream sequence of the VP5 promoter. DNA 
sequence between -75 to -125 relative to the cap site 
repressed the activity of VP5 promoter in uninfected cells, 
but it was required for maximum level of transactivation by 
superinfecting virus or by cotransfected IE genes39. R. H. 
Costa and E. K. Wagner suggested that all the modification of 
host cell's transcriptional machinery required for maximum 
expression of the VPS gene is accomplished by IE or E gene 
products or both, since inhibition of viral DNA synthesis 
increased CAT gene expression driven by VP5 promoter in 
infected cells. 
GOAL OF THIS STUDY 
25 
One of the major goal of herpes virus studies is to 
prevent not only the primary infection but also the recurrent 
infection. To achieve this goal, it is necessary to 
understand the molecular biology and pathogenesis of HSV 
infection. Studies of HSV gene regulation provides a major 
step towards this understanding. The regulatory mechanisms 
of late gene expression are less well characterized than 
those of immediately early genes and early genes. VP5 
promoter contains all the features of a typical eucaryotic 
transcriptional promoter. It is a good model for a leaky-
late gene in which the interaction of viral and cellular 
transcriptional factors and viral DNA control sequences can 
be studied. 
In the early studies of VPS promoter by other 
laboratories, viral IE proteins, ICPO, ICP4, ICP27, were 
found to be required for transactivation. But exactly how 
the three IE proteins transactivated VPS promoter, what cis-
acting sequence required, and if any cellular transcriptional 
factor(s) involved are unknown. By using mobility shift, 
competition binding assay, deletion mutant analysis and 
transient expression assays, I have carried out a series of 
studies to characterize and determine the function of viral 
and cellular factors, and the DNA sequences involved in the 
regulation of HSV-1 leaky late gene expression. These are 
the questions I have asked in this research project: 
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1) How do the HSV-1 Immediately-early proteins ICPO, 
ICP4, and ICP27 transactivate the VPS promoter? Is 
there any DNA sequence in the promoter that directly 
binds to viral protein(s)? Can any of the three 
protein be dispensed? 
2) Is there any cellular factor(s) involved in the 
transactivation? Are there specific HSV-1 VPS 
promoter sequences involved? How important is 
this DNA sequence in affecting the VPS promoter 
activity in both uninfected cells and HSV-1 infected 
cells? 
3) Is there any homology between the VPS binding site 
identified and other HSV ~y gene promoter sequences? 
Do they form the same or similar protein complexes? 
4) Do homologous or similar regulatory DNA sequence 
exist in other viruses? Is the same, or similar, 
cellular factor associated with them? What do we 
know about the function of this cellular factor? 
CHAPTER II 
MATERIALS AND METHODS 
MATERIALS 
Plasmids 
pVP5(-4/-168)CAT, pVP5(-4/-75)CAT and pVP5(-50/-168)CAT 
were kindly provided by E. Blair and E. Wagner, University of 
California, Irvine, CA. These plasmids contain VPS prornter 
-4 to -168, -4 to -75, and -50 to -168, respectively, linked 
to a reporter gene, the bacterial chloramphenicol acetyl-
transferase (CAT) gene and the EcoRI/SalI fragment of pBR322 
in which the 940 bp poison sequence was removed. The map of 
pVP5(-4/-168)CAT is shown in Figure 7, the wild type VPS 
promoter structure and sequence are shown in Figure 8. 
pGRlSOB was kindly provided by G. Hayward, Johns Hopkin 
University. pGR150B is comprised of the 23.7 kb BglII-HM 
fragment of HSV-2(333) which contains genes for irnrnediately-
early proteins IE175, IEllO, IE63 cloned into the BamHI site 
of pBR322· 
All of plasmid DNA were prepared by an alkaline lysis 
procedure of Brinboim and Doly59 . 
Enzymes 
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FIG. 8. A. Schematic representation of VPS promoter structure. B. The DNA sequences 
of VPS promoter. 
purchased from Bethesda Research Laboratories, Inc. and New 
England Biolab. They were used with the appropriate lOX 
reaction buffer supplied by the manufacturer. 
Exonuclease BAL 31, purchased from United States 
Biochemical Corporation, was used for exonucleolytic 
digestion. The Klenow fragment of DNA polymerase I, T4 DNA 
ligase, and RNase A, purchased from Bethesda Research 
Laboratories, Inc., were used for radioisotope labeling of 
DNA and construction of VPS promoter mutants. 
Radioactive Isotopes 
[a-32p]dCTP was purchased from NEN Research Products, 
Inc. at 3000 Ci/mmol. 3H-Na0Ac, 3.3 Ci/mmol, 10 mCi/ml was 
also purchased from NEN Research Products, Inc. 
Cells and Media 
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Hela cells (CCL2) were from American Type Culture 
Collection. Dulbecco's Modified Eagle (DME) medium, 
penicillin and streptomycin were purchased from GIBCO 
laboratories, Inc. Bovine calf serum and fetal bovine serum 
were purchased from Hyclone Laboratories, Inc. 
Virus 
The vhs-1 mutant of HSV-1 (KOS) was kindly provided by 
G. S. Read. It was derived by bromodeoxyuridine mutagenesis 
and it is defective in the virion associated host shut-off 
function responsible for the initial suppression of host 
protein synthesis. 
Nuclear Extract 
The nuclear extracts were kindly provided by Rosemary 
Lawn. They were prepared according to the procedure of 
Dignam et a1.60 from HeLa cells that were either mock 
infected or infected with HSV-1 for 8 hours. 
PREPARATION OF DNA PROBES 
Restriction digestion and DNA fragment isolation 
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Plasmid DNA was mixed with 1/10 total volume of lOX 
reaction buffer and 2-4 units restriction enzyme per µg DNA. 
Sterile distilled water was added to keep the enzyme 
concentration at or below 1/10 total volume and to dilute the 
lOX reaction buffer to lX concentration. The mixtures were 
incubated at 37°C, with the exception of BstNI which required 
60°C, for 2-6 hours. The incubation time depended on the 
activity of each enzyme (information provided by BRL) . 
Reactions were stopped by the addition of 1/10 volume of lOX 
stop-dye (50% (w/v) sucrose, 0.2 M EDTA, 0.25% bromphenol 
blue, 0.25% xylene cyanol FF). Samples were heated at 65°C-
700C for 3 minutes to prevent the annealing of cohesive 
termini and immediately chilled on ice and loaded into 
horizontal agarose gels. Agarose concentration in TBE buffer 
(0.089 M Tris-Cl, 0.089 M Boric acid, 0.02 M EDTA pH 8) 
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varied from 0.8-2.5% depending on the size of fragments. Gel 
was submerged in TBE buffer and run at 800-900 volt hours. 
Each gel also was loaded with known size markers along with 
DNA samples. The markers were bacteriophage lamda DNA 
digested with HindIII and PBR322 digested with AluI. 
Following electrophoresis, gels were stained for 10 minutes 
with 0.1 µg/ml ethidium bromide, destained for 10 minutes 
with water, then visualized under a long wave UV light, and 
photographed with Polaroid instant pack film 667. 
DNA fragments were isolated by electrophoresis onto DE81 
paper, and elution from 1 M NaCl, 0.1 mM EDTA, 10 mM Tris-Cl 
pH 8. The eluted DNA was extracted, once with phenol and 
chloroform (PCIA), once with chloroform and isoamyl alcohol 
(CIA), precipitated with ethanol, and redissolved in 0.089 M 
Tris-Cl pH 7.8, 0.089 M EDTA (TE) buffer to achieve the 
desired concentration61. DNA fragment concentration was 
estimated by electrophoresis on an agarose minigel along with 
different amounts of known DNA markers, and comparing the 
relative ethidium bromide staining intensities. 
DNA Labeling 
The 168 bp HindIII/SalI fragment of VP5(168)-CAT was 
isolated and labeled with [a-32p]dCTP by Klenow fill-in 
reaction62 as follows: DNA probe (0.5 µg) was mixed with 1/10 
volume of lOX nick translation buffer (0.5 M Tris-Cl pH 7.2, 
0.1 M Mgso 4 , 1 mM dithiothreitol, 500 µg/ml bovine serum 
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albumin) and 0.1 nmol of dATP,dTTP, dGTP, and 7.5 µCi [a-
32p]dCTP, 6-8 units of Klenow fragment in a total volume of 
40 µl. The mixture was incubated at 37°C for 30 minutes and 
cold chased by incubation with 2 mmol of dATP, dCTP, dGTP, 
and dTTP for another 15 minutes. One µmol of EDTA was added 
to stop the reaction. Following the Klenow fill-in reaction, 
the sample was extracted with PCIA and CIA, unincorporated 
nucleotides were removed by gel filtration through an 1 ml 
Sephadex G-50 spun column. The amount of [a-32p]dCTP 
incorporated during the Klenow fill-in reaction was measured 
by trichloroacetic acid (TCA) precipitation using a 
modification of procedure provided by Maniatis et al. 
MOBILITY SHIFT ASSAY 
A modification of gel mobility shift assay of Fried, M. 
and D. M. Crothers, was used to detect binding of potential 
regulatory proteins to the VP5 promoter region63. 
0.1-1.0 ng of DNA probe were mixed with 1.3 to 6.2 µg 
nuclear extract from either mock infected or HSV-1 infected 
Hep-2 cell in the presence of varying amounts (4 to 13.5 µg) 
of poly(dI-dC). Reaction buffer was added to achieve the 
final concentration of 6 mM Tris-Cl, pH 7.9, 40 mM KCl, 2 mM 
EDTA, 0.2 mM DTT, 8% (v/v) glycerol in a total volume of 
20ul. Reaction mixture were incubated at 37°C for 30 
minutes. Two µ1 of 0.25% bromphenol blue were added and the 
reaction mixture were analyzed by electrophoresis through 4% 
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polyacrylamide gels (acrylamide:bisacrylamide weight ratio of 
30:1) in 25 mM Tris-Cl, 25 mM Boric acid, 1 mM EDTA at 4°C. 
Gels were electrophoresed at 250 volts with buffer 
recirculated until bromphenol blue had run to the bottom of 
the gel, about 2 to 2.5 hours, and they then were transferred 
to Whatman 3MM paper, dried and autoradiographed with Fuji RX 
film with intensifying screen at -70°C for 24 hours. To 
quantify the amount of complexes formed, the intensity of 
each band was measured by LKB 2202 ultrascan laser 
densitometer. 
COMPETITION BINDING ASSAY 
A number of different viral and cellular promoters were 
tested for their ability to compete with protein binding to 
the VPS promoter. The competitors are listed in Table 2. 
Reaction conditions were as described in the gel mobility 
shift assay procedure except that the various nonradioactive 
competitor DNAs were added in 10-50 fold molar excess over 
the labeled DNA probe. 
PREPARATION OF MUTATED VPS PROMOTER CONSTRUCTS 
Strategy for construction of promoter mutations 
In order to test the function of the protein binding 
sequence of VPS promoter found in mobility shift assay, I 
constructed a series of pVP5(168)-CAT mutations in which the 
protein binding sequence was partially or completely deleted 
and the adjacent NF-1 consensus sequence was split. The 
strategy used for these construction is shown in Figure 9. 
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Fragment 1 was prepared by linearizing pVP5(168)-CAT 90 
ug with 180 units of SalI in a total volume of 250 ul. This 
fragment was subjection to digestion with exonuclease BAL 31 
as follows: First, a pilot reaction was run in order to 
determinate the exonuclease rate. Linearied plasmid DNA (8.3 
µg) was incubated at 30°C with 6 µ1 of Sx BAL 31 buffer (3 M 
NaCl, 60 mM MgCl2, 60 mM CaCl2, 100 mM Tris-Cl pH 8, 5 mM 
EDTA) and 2.25 units of BAL31 exonuclease. Fractions of 3 µl 
removed at 0, 2, 4, 7, 10, 15, 20, 30, 40 seconds, were 
subjected to electrophoresis in an 0.8% agarose gel. By 
measuring the fragment size in each fraction, I determined 
that approximately 125 bp at each end of the fragment were 
deleted within 40 seconds. 
Following the same procedure, 113 µl of the remaining 
linearized DNA were subjected to exonuclease BAL31 deletion. 
According to the deletion rate, fractions of 27 µl were taken 
after 23, 26, 29, 32, 35, 38 seconds of incubation. Three µ1 
of 0.5 M ethyleneglyclo-bis-<P-amino ethyl ether)N,N,N,N,-
tetracetic acid (EGTA) pH 8 was added to each fraction to 
stop the reaction. All fractions were pooled into one tube 
and extracted with PCIA and CIA, and then precipitated with 
ethanol. The dry DNA pellet was resuspend in 10 µl TE. 
Deleted fragments were digested with NcoI and fragments of 
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FIG. 9. Schematic representation of the strategy for constrution of VPS promoter 
mutations. 
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gel. The deleted/NcoI fragments were polished by filling in 
any non-blunt ends with the Klenow fragment according to the 
nick translation procedure as described above. 
BglII linker was purchased through New England Biolabs, 
Inc. T4 polynucleotide kinase and 5x kinase buffer, T4 DNA 
ligase and 5x ligase buff er were purchased from Bethesda 
Research Laboratories. BglII linker was phosphorylated by 
incubation with 1 µ1 10 mM ATP, 20 units T4 polynucleotide 
kinase and 1/5 volume supplied 5x kinase buffer at 37°C for 
30 minutes. 
Ligation protocol was provided by Maniatis et al. The 
deleted NcoI fragment (6.9 µg) and 1.25 µg BglII linker were 
mixed with Sul of 5x ligation buffer and 7 units of T4 DNA 
ligase, sterile distilled water was added to bring final 
volume to 25 µl. The mixture was incubated in l6°C for 16 
hours and the reaction was stopped by addition of one half 
volume of 7.SM NH40Ac. Three volumes of absolute ethanol 
were added and the DNA was allowed to precipitate at -20°C 
for 1 hour. The DNA was pelleted by centrifugation at 
10,000xg for 30 minutes at 4°C, vacuum dried. The DNA was 
digested with NcoI and BglII to generate NcoI/BglII fragments 
of 650-625 bp. These fragments were purified by gel 
electrophresis and isolated as described above. 
Fragment 2 was prepared by digesting 50 µg of pVP5(-
168)CAT plasmid with EcoI and XbaI. The 1200bp EcoRI/XbaI 
fragment was isolated and partially restricted with BstNI by 
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controlling the incubation time. The mixture of 78 bp and 95 
bp BstNI/Xba I fragments was isolated by gel electro-
phoresis. After a Klenow fill-in reaction to make blunt 
ends, phosphorylated BglII linkers were ligated to these 
BstNI fragments. Subsequent digestion with Bgl II and Sall 
generated the 84 bp and 101 bp BglII/SalI fragments. 
Fragment 3 was prepared by digesting 10 µg of pVP5(-
168)CAT plasmid with NcoI and Sall. The 3020 bp NcoI/SalI 
fragment was isolated by agarose gel electrophoresis. 
By using the same ligation procedure, equal molar 
amounts of fragments 1, 2 and 3 were ligated together using 
0.16 µg fragment 1, 0.02 µg fragment 2, 0.81 µg fragment 3, 
and 1 unit of T4 ligase in a total reaction volume of 16.9 
µl. Ligation reaction was carried out at +4°C for 16 hours. 
The ligation mixture was stored at -70°C. 
Selection of mutants 
Transformation. Competent HB101 cells were purchased 
through Bethesda Research Laboratories Inc. The transforma-
tion procedure was also provided by BRL. Ligation mixtures 
were diluted in TE (1:10). Aliquots of 0.8 µl that contained 
5 ng ligated VPS DNA were added to 20 µl HB101 cells and the 
mixtures were incubated on ice for 30 minutes. After 40 
seconds of heat shock in a 42°C water bath, the mixtures were 
chilled on ice for 2 minutes, then 80 µl SOC buffer (2% 
bacto-tryptone, 0.5% Yeast extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgCl2, 10 rnM MgS04, 20 mM glucose) was added and the 
mixture was shaked at 225 rpm for 1 hour at 37°C. Two 
additional transformation mixtures, one with the pBR322 DNA 
and the other without any DNA, served as controls. The 
transformation mixtures were streaked out on Luria Broth 
(LB) agar plates with 100 ug/ml ampicillin. To test the 
viability of HB101 competent cells, 20 µ1 of cells diluted 
into 100 µl of water were spread out on a LB agar plates 
without ampicillin. All plates were incubated overnight at 
37°C. 
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Restriction analysis. From the transformation, forty 
three ampicillin resistant colonied were picked and 
innoculated separately in 4 ml of Luria broth containing 50 
µg/ml ampicillin. Plasmid DNAs were prepared from each clone 
by a quick plasmid preparation. Each sample was analyzed by 
restriction endonuclease digestion. Pstl was used to 
linearize mutated DNA, EcoRl and Sall were used for three 
cuts, and EcoRl, Sall and Bglll provided four cuts in the 
recombinant plasmids. 
From the restriction analysis, eight mutant clones which 
appeared to contain the desired range of deletions in the VP5 
promoter sequences were selected. 
DNA sequencing. The plasmid DNAs from eight pVP5(-4/-
168)CAT mutants were obtained by large scale plasmid DNA 
preparation. 
i. Preparation of labeled DNA fragments 
The plasmid DNA from pVP5(-4/-168)CAT and its mutants 
were linearized by SalI digestion and labeled with [a-
32p] dCTP by Klenow fill-in reaction as described above. 
After a second digestion with PvuII, 32P-labeled SalI/PvuII 
fragments, ranging from 290 to 317 bp, were isolated from 
agarose gels. 
ii. DNA sequencing 
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A modification of Maxam-Gilbert protoco164, was used to 
determine the DNA sequences of mutated VPS promoters. For 
each end-labeled DNA fragment, a set of four reactions were 
set up: a) methylation of the DNA with dimethyl sulfate for 
cleavage at G sites. b) partial depurination in sodium 
formate provide in approximately equal cleavage at G sites 
and A sites. c) treatment with hydrazine for cleavage at C 
and T sites. d) treatment with hydrazine and sodium chloride 
to cleave only at C sites. 
Five µ1 of each sequencing reaction was loaded onto an 
8% polyacrylamide gel (acrylamide:bisacrylamide ratio 28:1, 
7.7 M Urea}. Electrophoresis was carried out at 1500-2000 
volts until the loading dye moved approximately two-thirds of 
the way down the gel. Gels were fixed in solution of 95% 
acetic acid and 5% (v/v) methanol for 10 minutes, and 
transferred to Whatman 3MM paper, vacuum dried, exposed to 
Fuji RX film for 48 hours at -70°C with KODAK intensifying 
screen. 
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TRANSFECTION AND CAT ASSAYS 
Transfection 
Four mutated VPS promoter constructs were selected for 
analysis. They were #2 in which the sequence from -83 to -93 
was replaced by BglII linker, #6 in which the BglII linker 
was inserted into the BstNI site in the NF-1 consensus 
sequence, #10 in which NF-1 site and half of the binding 
sequence were deleted, and mutant #13 in which NF-1 site and 
the binding sequence were completely deleted. (see Fig. 10). 
These mutant plasmids, along with the wild type pVP5(-4/-
168)CAT, were tested in transient-expression assays for CAT 
gene expression. 
Hela cells (CCL2) from American Type Culture Collection 
were propagated in Dulbecco's Modified Eagle (DME) medium 
containing 10% heat inactivated calf serum and 100 units/ml 
of penicillin, 100 µg/ml of streptomycin at 37°C, under a 5% 
C02 atmosphere. They were routinely passaged every 5 days at 
a 1:15 split ratio. 
Hela cells were seeded in 35-mm six-well cluster dishes 
at 3xl05 cells per well approximately 20 hours before 
transfection. After 17 hours, the medium was removed and 
cells were re-fed with 2.5 ml DME containing 10% heat 
inactivated fetal cattle serum and penicillin(lOO unit/ml) 
and streptomycin(lOO µl/ml) (DME+l0% IFCS+P/S). Three hours 
later, each 35 mm well of subconfluent monolayer was 
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FIG. 10. Mapping of deletion and insertion constructs in the VPS promoter. Insertion 
#6 contains an inserted BglII linker. Sequences between the arrows of all the 
deletion constructs were replaced by BglII linker. LBS and NF-1 consensus sequence 
were indicated. · 
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transfected with 0.5 ml DNA-calcium phosphate coprecipitates 
which contained 5 µg target plasmid and 11 µg carrier pUC18 
DNA or 8 µg target plasmid and 8 µg cotransfected effector 
plasmid, pGR150B65. Four hours after the DNA was added, the 
cells were shocked by adding to their medium 1 ml 15% 
glycerol in minimal essential medium for 1 minute, then the 
cells were washed with PBS-A (0.14 M NaCl, 2.7 rnM KCl, 4.3 rnM 
Na2HP04, 1.5 rnM KH2P04), and incubated further in DME+10% 
IFCS+P/S. Transfected cells were either superinfected with 
the vhs-1 mutant of HSV-1 at multiplicity of infection of 3 
for 20 hours after transfection, and harvested 26 hours later 
for CAT assay, or directly harvested for CAT assay 44 hours 
after DNA transfection. 
CAT assay 
The procedure of Nordeen et al. was used as a rapid, 
sensitive and inexpensive assay for chloramphenicol acetyl-
transferase activity66. 
Cell extract preparation. At 26 hours postinfection 
for virus superinfected cultures, the cell monolayers were 
washed twice with cell wash buffer (40 rnM Tris-HCl pH 7.4, 
150 mM NaCl, 1 mM EDTA), scraped from the cluster dishes and 
sedimented by low speed centrifugation. Cell pellets were 
resuspended in 100 µl 250 rnM Tris-HCl, pH 7.8. The cells 
were frozen at -20°C, thawed at room temperature for four 
times and then debris were removed by centrifugation at 
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10,000 rpm at 4°C for 10 minutes. Cell extracts were stored 
at -70°C. 
CAT enzyme assay. Chloramphenicol, ATP, bacterial 
chloramphenical acetyl transferase, S-acetyl coenzyme A 
synthetase, and coenzyme A were purchased from Sigma Chemical 
Company. 
Reaction mixtures containing 31.5 µl of 4x Assay buffer 
(400 mM Tris-HCl pH 7.8, 24 mM MgCl2, 300 mM KCl) were 
thoroughly mixed with 0.008 units of S-acetyl coenzyme A 
synthetase, 5 µ1 of 0.78 µCi/µl 3H-Na0Ac, 10 µl of SmM CoA, 4 
µl of lOOmM ATP and 0.5 µ1 of Chloramphenicol in a total 
volume of 95 µl. S-acetyl coenzyme A synthetase were added 
last to initiate the reaction. The reaction mixtures were 
incubated at 37°C for 30 min to generate labeled acetyl CoA. 
Thirty ul of cell extract was added and reaction mixtures 
were further incubated for 2 hours. The labeled 
chloramphenicol was extracted by vigorous shaking with 1 ml 
benzene. The benzene and aqueous phases were then separated 
by centrifugation in a microcentrifuge at 4°C for 15 minutes. 
An 800 µ1 aliquot of the benzene phase was placed in a 
plastic scintillation vial and dried by evaporation in a fume 
hood overnight. The residue was counted in 3 ml of 
scintillation fluid and radioactivity determined in a liquid 
scintillation spectroscopy, Beckman LS 9000. The CAT assay 
results were also confirmed by thin-layer chromatography and 
autoradio-graphy. After the 800 µl aliquots of the benzene 
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phase were dried in a fume hood overnight, they were 
redisolved in 50 µ1 of benzene and spotted on a KODAK silica 
gel thin-layer chromatography (TLC) plate. Chromatography 
was carried out with chloroform-methanol (95:5) as the 
solvent. The TLC plate was dried in a fume hood overnight 
and then exposed to Fuji RX X-ray film to visualize the 
acetylated chloramphani-col. After autoradiography, the 
labeled region of the TLC plate were excised and the 




The Complexes Formed by VPS LBS and YYl 
Promoter activities are regulated by the interaction of 
numerous site-specific DNA-binding proteins with their 
recognition sequences. A fundamental property of many site-
specific DNA-binding activators is their ability to stimulate 
transcription synergistically with other factors which 
recognize the same sequence or adjacent sequences. In the 
mobility shift assay in this study, two DNA-protein complexes 
were formed with both mock-infected and HSV-1 infected 
nuclear extracts. Although the VPS promoter is a typical 
eukaryotic promoter and requires three immediate-early 
proteins (ICPO, ICP4, and ICP27) for transactivation, there 
was no viral specific complex formed. The mobility shift 
result indicated that a cellular factor (or factors) is 
involved in the formation of the complexes and that the HSV-1 
immediatly-early proteins do not binds directly or only 
weakly bind to the VP5 promoter. 
Other HSV-1 promoters from different kinetic classes, 
and promoters from other viruses and some cellular genes, 
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FIG. 11. Gel mobility shift analysis of the VPS promoter. 
Various amount of nuclear extracts from either uninfected 
or HSV-1 infected HeLa cells were reacted with 0.1 ng of 
VPS promoter fragment (-4 to -168 bp relative to the cap 
site, end labeled with[a-32p]dCTP). Amount of nuclear 
extracts used, in micrograms of protein per reaction, and 
positions of the two major complexes (A and B) formed and 
free probe (P) are indicated. 
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were either mockinfected or infected with HSV-1 for 8 hours 
(Fig. 11). The reaction products were analyzed by 
electrophoresis on polyacrylamide gels. Two complexes were 
formed with both mockinfected or HSV-1 infected nuclear 
extracts. The larger complex, of lower mobility, was 
designated complex A and the smaller one was designated 
complex B. Although gene expression studies of immediately-
early gene mutants of HSV-1 have shown that ~y gene 
expression required viral IE proteins67, no viral specific 
complex was observed in this experiment. IE proteins may 
indirectly bind to VPS promoter or binds weakly to VPS 
promoter. This mobility shift assay result also indicates 
that some cellular factors are involved in forming the two 
complexes. 
To determine the promoter specificity of these 
complexes, a series of competition binding assays was carried 
out by using a number of different viral promoters. A 
HindIII/SalI fragment(-4 to -168 bp) of VPS promoter labeled 
with [a-32p]dCTP was used as probe, and the competing, non-
labeled DNA fragments used were promoters from HSV-1 genes of 
different kinetic classes. Since the protein binding sites 
LBS previously identified in the VPS promoter overlapped with 
a nuclear factor-1 (NF-1) consensus sequence, a DNA fragment 
containing the NF-1 sequence of adenovirus-2 was also tested 
in the competition binding assay (see Table 1) . The results 
of these experiments (some presented in Figure 12) indicate 
TABLE 1. VARIOUS SEQUENCES TESTED IN THE MOBILITY SHIFT ASSAY 
Competitor Fragment and Source 
1. 430 bp PstI/KpnI fragment of pCA23 
190 bp AvaII fragment of pCA23 
2. 370 bp EcoRI/SstII fragment of pDII 
3. 200 bp HindIII/KpnI fragment of p2.7-CAT 
4. 214 bp PstI/PvuII fragment of pHSV-106 
5. 620 bp SmaI/PstI fragment of HSV-106 
Content 
a-TIF promoter 
NF-1 site of adenovirus-2 
UL14/15 (2.7 py gene) promoter 
5.2 kb py gene promoter 
HSV-1 gH promoter 
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that none of the promoter fragments I tested compete with the 
VP5 promoter DNA in the formation of complexes A and B. 
Likewise, the failure of the adenovirus-2 NF-1 DNA fragment 
to compete suggests that the NF-1 consensus sequence present 
on the VP5 promoter is not responsible for complex A and B 
formation. However, Millette's results68 showed that the 
HSV-1 promoters gD and gB, and an internal fragment of the 
UL37 gene competed with VP5 promoter to form the complexes. 
These results, taken together with others from Millette's 
lab, indicate that the observed complexes are very likely 
specific for the VP5 promoter and certain ~y genes of HSV-1 
(see Table 2). 
To determine the boundaries of the VP5 DNA sequences 
involved in the formation of complexes A and B, two 
subfragments of the VPS promoter region were used, VPS(-
4/-75), containing the sequence from -4 to -75 and VP5(-50/-
168), containing the sequence from -50 to -168 relative to 
the mRNA cap site (see figure 13) . They were excised from 
plasmid pVP5(-4/-75)CAT and pVP5(-50/-168)CAT respectively. 
In the first experiment, a [a-32p]dCTP labeled HindIII/SalI 
fragment of the VP5 promoter, VPS(-4/-168), was used as 
probe, and 50-fold molar excess amount of VP5 promoter 
subfragments were served as competitors. Both the VP5(-4/75) 
and VP5(-50/-168) competed. In the second experiment, a [a-
32p]dCTP labeled VP5(-50/-168) fragment was used as probe 
while 50-fold molar excess amount of non-labeled VPS(-4/-75) 
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FIG. 12. Competition of VPS promoter complex formation by unlabeled DNA fragments. 32P-labeled VPS(-4/-
168) promoter and 3.7 µg of protein of infected HeLa nuclear extract presented in all reactions. All 
Lane 1 were probe only. Lane 4 in A, lane 2 in B and C, are positive control, which 40-fold molar excess 
of unlabeled VPS(-4/-168) were used as competitor. A. Lane 2 and 3, 20-·and 40-fold unlabeled UL14/UL15 
fragment as competitor, respectively. B. lane 3 and 4, 20- and 40-fold 190 bp a-TIF promoter as 
competitor; lane 5 and 6, 20- and 40-fold 430 bp a-TIF promoter as competitor. C. lane 3 and 4, 20- and 
40-fold unlabeled 370 bp fragment which contains adenovirus-2 NF-1 site as competitor. 
Table 2. Competition of VPS Promoter Complex Formation by 







DNA fragments showing: 
No competition 





VPl 6 (~y) 
TK 
UL40 (p) 
ICP4 7 (a) 






gB +136 (py) 
UL 3 7 + 7 5 0 ( p or py) 
VP5(-4/-168) 
NF-1 consensus LBS Hind 111 
Sal I CAT box sequence SP1 TATA box er 
I lccAATIHrfGGACCAGGGCC~TCITGAA IGGGCGGH TATATAAI 
-1 68 -107 -101 -85 - 71 -38 -28 -25 - 1 8 -4 
V P 5 { - 5 0 I - 1 6 8 ) LBS 
I I CCAA TIHrfGGACCAGGGCC~ TCITGAA-1 
-1 68 -50 
LBS 
VP5(-4/-75) 
lGGCC1 TCITGAA IGGGCGGH TATATAAI I 
-75 -4 
FIG. 13. Diagram of VPS(-4/-168) promoter and its subfragments, VPS(-4/-75) and 
VP 5 ( - 5 1 I -1 6 8 ) . 
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served as competitor; the VP5(-4/-75) fragment showed good 
competition (see figure 14) . These results indicate that 
complexes A and B involve DNA sequence located in the overlap 
region of the two VP5 promoter subfragments, the sequence 
from -50 to -75 relative to the cap site. 
DNase I footprinting and orthophenanthroline-cu+ 
analysis68 confirmed the location of complexes. The results 
show that Complex A involves the sequence from -64 to -75, 
and complex B involves sequence from -63 to -76 relative to 
the VP5 cap site. Both complexes encompass a common core 
promoter sequence GGCCATCTTGAA , designated the Leaky-late 
Binding Site (LBS), located from -64 to -75 relative to the 
cap site (see figure 15). 
ANALYSIS OF MUTANTS 
Complex formation by the mutated VP5 promoters 
To assess the role of the VP5 promoter Leaky-Late 
Binding Site (LBS) in the transcriptional regulation of the 
VP5 gene, a series of mutated VP5 promoter constructs were 
generated from pVP5(-4/-168)CAT by deletion and insertion 
around the protein binding site LBS. The isolation procedure 
involved, in brief, opening pVP5(-4/-168)CAT at a BstNI site, 
exonucleolytic digestion with nuclease BAL 31, connecting an 
8 bp BglII linker, and ligating the appropriate fragment back 
together (See Materials and Methods) . The mutant constructs 
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#1 #2 #3 #4 
VPS(-51 /-168) Probe + + + + 
VPS(-51 /-168) fragment SOx 
VPS(-4/-75) fragment 20x 50x 
Nuclear Extract, Poly(dl-dC) + + + + 
FIG. 14. Competition binding assay between the VP5(-4/-168) promoter and its 
subfragments. A. VP5(-4/-168) as probe. Lane 1, probe only, without competitor; lane 
2-4, unlabeled 50-fold molar excess of VP5(-4/-168), VP5(-51/-168), and VP5(-4/-75), 
respectively. B. VP5(-51/-168) as probe. Lane 1, probe only; lane 2, unlabeled SO-fold 
molar excess of VP5(-51/-168); lane 3 and 4, unlabeled 20 and SO-fold molar excess 
VPS(-4/-75). 3.7 µg of protein of infected HeLa nuclear extract presented in all lanes. 
Poly(dI-dC) were used for nonspecific binding. 
Location of Complex A and B 
Sall CAT BOX NF-1 SP1 TATA Hind Ill 
I I ~TCTTCCTGGC ACGCTTT_T_G_G __ A_C_C_A_G_G_G_C_C_A TCTTGAATGC - · AGAAGGACCG TGCGAAAACC TGGTCCCGGT AGAACTTACG ACCCGTCGC~--1 TGGGCAGCGC 
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B 
FIG. 15. Diagram showing protected regions of the VPS promoter in DNase I footprint 
assay. The VPS TATA box and potential Spl, CAT box, and NF-1 sites are indicated. 
-4 
MUTATED VP5 PROMOTERS 
Sall CAT box NFsi~8~~g~sus SP1 TATA box Hind 111 
I ICCAATII fITGGACCAGGGCCAI . ICilm3 H TATATAAI Cj 
-168 I -107 -101 -85 ~1 I ·38 -28 -25 -18 -4 
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Bgl II linker 
#13 
FIG. 16. Diagram of mutated VPS promoters tested in this project. Insertion #6 
contains an BglII linker. Sequences between the arrows of all the deletion 
constructs were replaced by an BglII linker. LBS and NF-1 consensus sequence were 
indicated. 
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They were construct #2 in which sequence from -83 to -93 was 
deleted, #6 which contained an 8 bp Bgl II linker insertion 
between -80 to -81 thereby splitting the NF-1 consensus 
sequence, #10 in which the sequence from -70 to -93 
containing NF-1 consensus site and half of LBS was deleted, 
and #13 in which the NF-1 consensus site and the LBS were 
completely deleted. 
Mutated VPS promoter from constructs #2, #6, #10 and #13 
were tested as competitors in competition binding assay to 
determine the relation between promoter sequences and the 
ability to form complexes A and B. The molar ratio of 
radiolabeled probe to the competitor was 1:20 and 1:40, (See 
Figure 17). The results of these experiments showed that the 
mutated VPS promoter of mutant constructs #2 (data not shown) 
and #6 were capable of competing as well as the wild-type VP5 
promoter, whereas the mutated VPS promoter of #10 only 
partially competed and that of #13 completely failed to 
compete. These data indicate that the deletion of sequence 
from -83 to -93 in construct #2 and the 8 bp insertion 
between -80 and -81 in #6 does not affect the formation of 
complexes A and B. Deletion of sequence from -70 to -93 in 
construct #10 partially affects the formation of both 
complexes and the deletion of sequence from -59 to -93 in 
construct #13 completely eliminates complex formation. 
Therefore, sequence from -80 to -59 is most likely involved 
in the formation of both complexes directly. 
#1 #:2 #3 #4 .ftS -#6 t7 #8 #9 #10 #11 #12 #13 
wt. VP5 A#10 A#13 wt. VPS \1#6 
f ------. I ----m I I I I I I . 
A .... ~·· ..... - -
B 
p 
FIG. 17. Competition binding of labeled VPS promoter versus unlabeled mutated VP5 
promoter fragments. Gel mobility shift assay was carried out with 3.7 µg of protein 
of infected HeLa nuclear extract. A, B, and P, complexes A and B and free probe 
respectively; lane 1, free probe; lane 2 and 9, 32p labeled VPS(-4/-168) without 
competitor. For the remain lanes, 20- and 40-fold molar excesses of the indicated 
wild-type or mutated VPS promoter fragments were used as competitors. 
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The promoter activity in transient expression assay 
To analyze the role of the complexes in the regulation 
of VPS gene expression, the wild-type VPS promoter (sequence 
-4 to -168) and mutated VPS promoters were tested in 
transient expression assays with or without viral trans-
acti vation to investigate the effects of the mutation on 
promoter ability to drive expression of the bacterial 
chloramphenicol acetyl transferase gene at both basal level 
and induced level. 
Hela cells were transfected with either wild-type VPS(-
4/-168}-CAT or mutated VPS promoter constructs. The cells 
were either harvested 45 hours after transfection, or they 
were superinfected with the vhs-1 mutant of HSV-1 KOS strain 
24-26 hour after transfection, and then harvested 26 hours 
later. These results are presented in Figure 18. Without 
viral transactivation, both wild type VP5 promoter and 
mutated VPS promoters were basically inactive. The levels of 
CAT expression driven by these promoters were essentially 
same as that in the untransfected cell. With virus 
superinfection, however, CAT activity of VP5(-4/-168}CAT 
increased 424 fold whereas construct #6 having an 8 bp 
insertion disrupted the NF-1 consensus sequence increased 351 
fold. As with construct #6, the deletion in construct #2 
had only a small effect in CAT activity(data not shown}. 
Deletion of half of LBS (#10} reduced the transactivaion 
level to 92 fold whereas deletion of all LBS (#13) produced 
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FIG. 18. Induction of transfected VP5 promoter-CAT 
constructs by HSV-1 superinfection. Amount of acetylated 
chloramphenicol produced is expressed as picomoles of the 
monoacetylated form produced in 2 hours at 37°C with 25 
µl of cell extract. U represent uninduced levels, and I 
represents induced levels. Number on the bar graph 
indicate fold-induction over uninduced levels. Average 
uninduced CAT levels was 5.6 pmol of acetylated 
chloramphenicol. The data represent averages of a minimum 
of three separate transfection assays. 
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only 51 fold induction by superinfecting virus. Therefore, 
deletion of LBS resulted in about 8-fold reduction in the 
level of viral transactivation of the VP5 promoters. These 
results suggest that the LBS may activate the VPS promoter by 
binding to the cellular factor and this is required for the 
maximum VPS expression under viral superinfection. 
Early studies HSV-1 mutations in other laboratories 
have reported that three HSV-1 IE genes (encoded ICPO, ICP4, 
and ICP27) were required for VP5 promoter activation. The 
requirement of all three viral proteins was tested in the 
transient expression assay. Plasmid pGR150B contains the 
immediate-early gene ICPO, ICP4 and ICP27. Plasmid pGR90 
contains ICPO, ICP4 and ICP47 gene, and pGR162 contains ICP27 
gene only. Plasmid pVP5(-4/-168)CAT along with one of the 
above plasmids were used to cotransfect the cells. The CAT 
activity induced by pGRlSO was 69.8 times over the uninduced 
level, whereas the CAT activities induced by either pGR90 or 
pGR162B remain about the same as the uninduced level (see 
Fig. 19). This comfirmed the necessity for all three 
immediately-early viral proteins in VPS transactivation. 
The involvement of LBS in the viral proteins trans-
acti vation process was tested in further transient expression 
assay. Cotransfected plasmid, pGRlSOB provided the three 
viral immediately prot\~in:3 (ICPO, ICP4, and ICP27) required 
for activating late gene promoters (see figure 19) . The 
results showed that transactivation by IE genes increased CAT 
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FIG. 19. Induction of transfected VPS promoter-CAT 
constructs by cotransfected plasmid, pGR150B, contains 
RSV genes for ICPO, ICP4, and ICP27. Amount of acetylated 
chloramphenicol produced is expressed as picomoles of the 
monoacetylated form produced in 2 hours at 37°C with 25 
µl of cell extract. U represent uninduced levels, and I 
represents induced levels. Number on the bar graph 
indicate fold-induction over uninduced levels. Average 
uninduced CAT levels was 5.6 pmol of acetylated 
chloramphenicol. The data represent averages of a minimum 
of three separate transfection assays. 
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activity of pVP5(-4/-168)CAT 69.8 fold over the uninduced 
level, whereas #6 increased it 30.5 fold, #10 increased it 
13.6 fold, and #13 increased it only 9.6 fold. Thus deletion 
of the LBS resulted in a 7.1 fold reduction in gene 
expression relative to that of the wild type VPS promoter. 
These results indicate that even though the LBS has not been 
shown to directly associate with viral proteins, it is 
required for optimal level of transactivation by 
superinfecting HSV-1 or cotransfected HSV-1 IE proteins. In 
addition, the LBS sequence appears to have no effect on the 
uninduced level of promoter activity. 
A Computer search of GeneBank has shown that homologies 
to LBS exist in many viral genes and cellular genes. The 
homologies and their locations are listed in Table 3. 



















































































tctCCATtTTGA (YYl site) +l (cap) 
GcGaCATtTTGc (YYl site) -60 (cap) 
GGCCATCTTGA (µEl site) enhancer 
GaCCTtTTct (CFl site) -260 (cap) 





The Complexes Formed by VPS LBS and YYl 
Promoter activities are regulated by the interaction of 
numerous site-specific DNA-binding proteins with their 
recognition sequences. A fundamental property of many site-
specific DNA-binding activators is their ability to stimulate 
transcription synergistically with other factors which 
recognize the same sequence or adjacent sequences. In the 
mobility shift assay in this study, two DNA-protein complexes 
were formed with both mock-infected and HSV-1 infected 
nuclear extracts. Although the VPS promoter is a typical 
eukaryotic promoter and requires three immediate-early 
proteins (ICPO, ICP4, and ICP27) for transactivation, there 
was no viral specific complex formed. The mobility shift 
result indicated that a cellular factor (or factors) is 
involved in the formation of the complexes and that the HSV-1 
immediatly-early proteins do not binds directly or only 
weakly bind to the VP5 promoter. 
Other HSV-1 promoters from different kinetic classes, 
and promoters from other viruses and some cellular genes, 
were tested in competition assay. Most of them were not able 
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to form the complexes, except the gD promoter, a fragment 
from the nontranslated leader region of gB, and a UL37 gene 
fragment (see Table 2) . These genes, like VP5, all belong to 
the HSV-1 ~y kinetic class. Further studies from the 
Millette labortory showed that the promoters of HSV-1 gB, go 
and human c-myc gene competed with the VPS promoter by 
binding to the same protein68. 
There is a consensus nuclear factor-1 (NF-1) binding 
site upstream of the LBS that partially overlaps with the 
LBS. NF-1 was originally isolated from HeLa nuclei as a host 
factor required for efficient initiation of adenovirus DNA 
synthesis in vitro69. Subsequently, NF-1 was shown to be 
identical to the cellular factor CTF (CCAAT-binding 
transcription factor) and play a role in transcription70. A 
number of NF-1 binding sites have been identified upstream of 
various cellular and viral genes. In this study, partial 
deletion of LBS and NF-1 consensus binding site in mutant #10 
reduced complex formation, and complete deletion of LBS and 
NF-1 consensus binding site in mutant #13 resulted in 
elimination of the complexes. The involvement of NF-1 
consensus sequence to the protein-DNA complexes was tested in 
competition binding assay. A forty-fold molar excess of a 
DNA fragment which contains an adenovirus-2 NF-1 site and 
origin was unable to compete with the VPS promoter sequence 
to form the complexes. Also, An 8 bp insertion in the middle 
of the NF-1 consensus site of mutant #6 did not change the 
ability of VPS promoter to form the complex. Therefore, it 
is unlikely that the NF-1 is involved in the formation of 
complex A and B .. 
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By treating the DNA/protein complexes with V8 
endoprotease, Millette and Mill's partial proteolysis study 
revealed the similar subcomplex patterns among the complexes 
formed by VPS promoter, gD promoter or human c-myc promoter 
with nuclear extract, and complexes formed by VPS promoter 
with YYl protein71. They also showed that a monoclonal 
antibody to YYl inhibited formation of complexes A and B. 
Their result indicated that the protein which forms the 
complexes A and B is cellular factor YYl. 
Based on following observation in their laboratory, 
Millette and Mills suggested that the smaller complex (B) 
results from proteolytic cleavage of the YYl protein that 
forms complex A, and either two forms of YYl exist in the 
cell or they were formed during nuclear extract preparation: 
1) DNase I and orthophenanthroline-cu+ footprint analysis68 
showed that complex A and B formed over a core sequence 
GGCCATCTTGAA (LBS) located from -64 to -75 relative to Cap 
site. 2) A radiolabeled oligonucleotide containing only the 
LBS site formed both complexes. 3) V8 endoprotease digestion 
of the nuclear extract complexes resulted in the same pattern 
of subcomplexes as that observed with the YYl complex. 4) A 
monoclonal antibody to YYl inhibited formation of both 
complexes. 
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The Effect Of LBS In VP5 Transactivation Of Viral Factors 
Previous studies of Smiley and Everett using DNA 
transfection showed that the VP5 promoter was relatively 
inactive in uninfected cells, but it was effectively 
transactivated by a superinfecting virus, HSV-1, or by three 
immediately early gene products: ICPO, ICP4 and ICP27. 
In Costa and Wagner's early study, the activities of 
different length VP5 promoters were tested in transient 
expression assays. The VP5 promoter sequence from +1 to -75 
had detectable activity in uninfected HeLa cells, whereas the 
VP5 promoter sequence from +1 to -125, +1 to -168, or +1 to 
-650 were completely inactive in transfected HeLa cells in 
the absence of HSV induction. However, with HSV-1 infection, 
even though the the VP5 promoter sequences +1 to -75 was 
sufficient to allow expression with HSV superinfection, it 
induced at least 10 fold less CAT expression than that of 
VP5 promoter from +1 to -125, +1 to -168, or +1 to -650. In 
addition, no more than 125 bp of VP5 promoter was found to be 
sufficient for the maximum expression. This suggested that 
some feature of the VP5 promoter sequence between -75 to -125 
blocked the uninfected cell's ability to recognize the VP5 
promoter in the CAT expression assay and that this region of 
the VPS promoter may also be involved in achieving full 
activity from this promoter after HSV superinfection55. 
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In my research project, wild-type VPS promoter(-4/-168) 
and mutated VPS promoters, ranged from -59 to -93 relative to 
cap site, were tested in transient expression assays to 
elucidate the effects of the mutation on promoter activity. 
Wild type VPS promoter and all mutated VPS promoters have 
undetectable activity in uninfected cell. This result 
further suggest that the sequence from -94 to -125 may have a 
blocking or repressing effect. CAT gene expression driven by 
wild-type VP5 promoter increased 425 fold with HSV-1 
superinfection over that of uninfected control. Insertion of 
8 bp in the middle of NF-1 consensus sequence, as well as 
deletion from -82 bp to -93 bp in #2, slightly reduced CAT 
gene expression. Deletion of complete protein binding site 
and NF-1 consensus sequence resulted in only 51 fold 
induction. This amounted to a 8.3-fold reduction in viral 
transactivation, and a level of CAT gene expression that was 
only 13% that of wild type. Similar results were obtained 
from co-transfection of VP5 promoters with a plasmid 
containing genes for three HSV immediately-early proteins, 
ICPO, ICP4, and ICP27. These results suggest that LBS plays 
an important role in optimal level VPS gene expression. The 
increase in expression mediated by the NF-1 binding site may 
be is additive with, and independent of, the enhancement by 
the VPS LBS. The significance of each should be tested in 
transient assay by deletion of either NF-1 consensus site or 
the protein binding site, LBS. Complete deletion of LBS in 
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VPS promoter did not reduce promoter activity to the control 
level. This suggested that another region of VPS promoter 
also must be involved in the transactivation process, and 
that interaction of multiple factors may be required for 
maximal transactivation of the VPS promoter. 
A Computer analysis of GeneBank have shown that 
homologs of LBS exist in many viral genes and cellular genes. 
The homologs and their locations are listed in Table 3. In 
HSV-1, several late genes showed sequences highly homologous 
to LBS. Millette's data showed that three other HSV-1 py 
promoters(gB, gD, and UL37) competed for the factor binding 
to LBS; two potential PY promoters (UL14/15, UL24) did not 
compete. In Everett's early study of gD promoter, deletion 
analysis showed that the promoter region which contains the 
LBS homolog was very critical for viral transaction of the 
gene. The VPS promoter of Varicella-Zoster virus, and the 
late promoter of human papillomovirus-5 also contain LBS 
homologs. 
The most interesting finding is the existance of LBS 
homologs in the long terminal repeat of many retroviruses. 
These include both simian retrovirus 1 which causes simian 
acquired immune deficiency syndrome (SAIDS), and simian 
retrovirus 2 which induces retroperitoneal fibromatosis in 
addition to SAIDS. These LTRs contain 8 to 14 bp of LBS 
homologies located about 130-150 bp upstream from the mRNA 
start site. Millette's laboratory found that a fragment of 
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the SRV-1 LTR that contains a 14 bp perfect match to the VPS 
LBS formed two complexes of similar mobility to the VPS 
complexes, and an oligonucleotide containing the VPS LBS 
effectively competed with the SRV-1 fragment for cellular 
protein binding68. LBS homologies also occur in the long 
terminal repeat of human AIDS virus HIV-1 and a human retro-
provirus, and deletion studies have shown this region of the 
long terminal repeat may play a role in transcriptional 
regulation. Herpes simplex virus 1 and 272, cytomegalo-
virus 73, and human herpesvirus 674 are among of a number of 
viruses have shown be able to activate gene expression driven 
by the HIV long terminal repeat and enhancer. Even though no 
specific binding between ICPO and HIV-1 LTR found, the 
transfection study of Pitha et al. have showed that ICPO can 
activate the HIV-1 long terminal repeat promoter region and 
the effect of ICPO can greatly enhanced in the presence of 
cellular factor NF-KB75. The Spl sites located on the HIV-1 
LTR also served as target sites of transactivation by HSV-
176. The next interesting question is, does the VPS LBS 
homolog in the HIV long terminal repeat play a role in the 
transactivation of HIV. 
The recognition site for common factor I (CFl) in the 
cellular immunoglobin heavy chain enhancer, skeletal a-actin 
promoter, and c-myc promoter also showed homologies with LBS. 
CFl, a protein which binds the upsteam of the murine c-myc Pl 
promoter, was identified by mobility shift assay and 
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footprint assay77. The CFl binding activity was found in all 
cultured cells and normal tissues tested78. Riggs et al. 
have recently published results showing that CFl is identical 
to yy179. 
YYl, also known as NF-El, UCRBP, and B, is a ubiquitous-
ly expressed zinc finger protein. The binding sites for YYl 
are widely distributed in many cellular and viral 
promoters80. In many instances, YYl act as a transcriptional 
repressor81,82, e.g. in the adeno-associated virus PS 
promoter, immunoglobulin K3' enhancer, and c-fos promoter, 
etc., whereas in other cases it appears to be an activator of 
transcription83, for example, in the c-myc promoter, and IgH 
intronic enhancer. In Natesan and Gilman's paper, they 
presented the evidence that YYl regulates the activity of the 
c-fos promoter primarily through an effect on DNA structure. 
YYl binds to the promoter and induced a phased DNA bend at 
three sites. YYl repressed the c-fos promoter activity, but 
activated the same promoter when the YYl binding site was 
reversed. They concluded that the major function of YYl in 
c-fos promoter is to bend DNA to regulate contact between 
other proteins84. In the case of HSV-1, it is possible that 
the bending of VP5 promoter caused by YYl enhances the 
interaction between general transcription factor and Spl or 
CAT box binding protein. Finally, there are several reports 
about the physical interaction between YYl and Sp185. This 
suggest that Spl may exert its effect on VP5 promoter 
activity in an indirect way by affecting how YYl interacts 
with VPS. 
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DNA bending and looping play an important role in the 
regulation of transcription, replication and recombination in 
bacteria86, 87. Many mammalian transcription factors have 
been reported bend DNA88,89. Natesan and Gilman suggested 
that some transcription factors, e.g. YYl, may have no 
intrinsic activation or repression function of their own, but 
may induce structural changes such as bends in the DNA helix 
to facilitate other protein-DNA interaction. It will be 
interested to investigate the YYl function when the LBS 
orientation reversed. 
Some of the VPS LBS homologs are found in introns or 
the coding sequences of other viral genomes and cellular 
genes. It is hard to determine the significance at this 
point, but an increasing number of intragenic elements which 
affect gene transcription have been reported90, and some 
researchers have reported regulatory elements that are 
located within protein-encoding sequences91. 
In summary, the research findings in this project are 
presented as following: 1) Two DNA-protein complexes were 
formed with the HSV-1 VPS promoter. The VPS regulatory 
sequence, LBS, is responsible for the formation of these 
complexes, and the cellular protein involved, later proved by 
Millette and Mills, is YYl. 2) Mutation analysis showed that 
the LBS is required for maximum levels of VP5 transactivation 
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either by superinfecting HSV-1 or by cotransfected IE HSV-1 
genes, ICPO, ICP4, and ICP27. 3) Homologs of the LBS occur 
throughout the HSV-1 genome and other viral genome, as well 
as some cellular genes. Millette and Mills showed HSV-1 gD, 
gB, and UL37 genes also form the complexes with YYl. This 
suggested that the regulation in VPS is very likely relevant 
to several other HSV-1 ~y genes. Some of the homologs 
studied in other laboratories, for example, the homologs in 
adeno-associated virus PS promoter and in immunoglobulin 
heavy chain enhancer, have shown to play an important role in 
the transcription regulation. 
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